Firm Advises Ahren, OMX Ventures, +ND Capital, and Fine Structures Ventures on Constructive Bio’s $58 Million Series A

On September 24, 2024, Constructive Bio, a pioneering synthetic genomics company, announced that it has secured $58 million in the first close of its Series A financing, bringing the total amount raised by the company to date to $75 million. The round was led by Ahren Innovation Capital, OMX Ventures, and Paladin Capital Group with participation from Fine Structure Ventures, +ND Capital, and Abcam-founder Jonathan Milner. Wilson Sonsini Goodrich & Rosati advised Ahren, OMX Ventures, +ND Capital, and Fine Structures Ventures on the transaction.

The Series A investment will be used to further develop Constructive Bio’s groundbreaking technology that writes genomes from scratch and creates entirely new biomolecules.

The Wilson Sonsini team that advised Ahren, OMX Ventures, +ND Capital, and Fine Structures Ventures on the transaction included:

Corporate
Michael Labriola
Diviya Padman
Conor Cannon
Stacy Kim
Ashmi Bhagani
Betty Rosenbaum
Rashad Mohammed

National Security
Mike Casey
Stephen Heifetz
Nimit Dhir
Navpreet Moonga

Patents and Innovations
Lou Lieto
Wei Huang
Lisa Nip
David Stanton

Technology Transactions
Rodrigo Valle
Waen Yoon

For more information, please see Ahren’s press release.